Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P56703
UPID:
WNT3_HUMAN
Alternative names:
Proto-oncogene Int-4 homolog
Alternative UPACC:
P56703; Q2M237; Q9H1J9
Background:
Proto-oncogene Wnt-3, also known as Int-4 homolog, plays a pivotal role in the canonical Wnt signaling pathway, activating TCF/LEF family transcription factors. Essential for early embryogenesis, it orchestrates gastrulation, primitive streak formation, and mesoderm development. It's crucial for limb formation and the development of the apical ectodermal ridge.
Therapeutic significance:
Linked to Tetraamelia syndrome 1, characterized by limb agenesis and various organ anomalies, Wnt-3's involvement suggests potential therapeutic targets. Understanding the role of Proto-oncogene Wnt-3 could open doors to potential therapeutic strategies for this autosomal recessive disease.